Financial reports
ARS
2023 FY
Annual report to shareholders
22 Apr 24
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
6 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
14 Mar 22
Current reports
8-K
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
12 Apr 24
8-K
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
6 Mar 24
8-K
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
27 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Feb 24
8-K
Other Events
31 Jan 24
8-K
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
4 Jan 24
8-K
Other Events
6 Dec 23
8-K
Other Events
14 Nov 23
8-K
Adaptimmune Reports Third Quarter Financial Results and Business Update
8 Nov 23
8-K
Departure of Directors or Certain Officers
3 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
30 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jun 23
425
Business combination disclosure
30 May 23
425
Business combination disclosure
22 May 23
424B3
Prospectus supplement
20 Apr 23
S-4
Registration of securities issued in business combination transactions
5 Apr 23
425
Business combination disclosure
9 Mar 23
425
Business combination disclosure
9 Mar 23
Proxies
DEF 14A
Definitive proxy
11 Apr 24
PRE 14A
Preliminary proxy
1 Apr 24
DEF 14A
Definitive proxy
13 Apr 23
PRE 14A
Preliminary proxy
3 Apr 23
DEF 14A
Definitive proxy
21 Apr 22
PRE 14A
Preliminary proxy
11 Apr 22
DEF 14A
Definitive proxy
8 Apr 21
PRE 14A
Preliminary proxy
29 Mar 21
DEF 14A
Definitive proxy
20 Apr 20
PRE 14A
Preliminary proxy
8 Apr 20
Other
EFFECT
Notice of effectiveness
21 Apr 23
CORRESP
Correspondence with SEC
18 Apr 23
UPLOAD
Letter from SEC
6 Apr 23
EFFECT
Notice of effectiveness
25 Apr 22
CORRESP
Correspondence with SEC
21 Apr 22
UPLOAD
Letter from SEC
15 Apr 22
CT ORDER
Confidential treatment order
4 Nov 20
EFFECT
Notice of effectiveness
11 Sep 19
UPLOAD
Letter from SEC
6 Sep 19
CORRESP
Correspondence with SEC
6 Sep 19
Ownership
SC 13D/A
New Enterprise Associates 14, L.P.
2 Apr 24
3
Initial statement of insider ownership
26 Mar 24
SC 13G/A
EcoR1 Capital, LLC
26 Mar 24
4
Cintia Piccina
18 Mar 24
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G
EcoR1 Capital, LLC
30 Jan 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
4
Adrian Rawcliffe
17 Jan 24
4
Elliot Norry
17 Jan 24